MediNatura New Mexico, Inc. has issued a voluntary recall of one lot of ReBoost Nasal Spray across the United States due to the detection of microbial contamination. This recall, announced on December 10, 2025, aims to protect consumers, particularly those who are immunocompromised, from potential risks. Clinical, quality, and regulatory professionals, as well as healthcare providers, may need to assess implications for their organizations or patients.
What led to this recall?
The ReBoost Nasal Spray recall stems from findings of yeast, mold, and microbial contamination within the product, including the identification of Achromobacter species at levels exceeding acceptable specifications. According to MediNatura, this contamination could cause adverse health outcomes, with the greatest risks being posed to immunocompromised individuals who may develop life-threatening infections.
Affected product details
The recalled ReBoost Nasal Spray belongs to lot number 224268 and carries an expiration date of December 2027. This homeopathic nasal spray, intended to alleviate symptoms like nasal congestion, sinus headaches, postnasal drip, sneezing, and itching, is packaged in 20 mL bottles within white and yellow cartons. Consumers can identify the product using its NDC number 62795-4005-9 and UPC number 787647 10186 3. MediNatura distributed this lot nationwide through retail outlets and its website.
Consumer guidance for recall response
MediNatura advises customers to halt the use of all ReBoost Nasal Spray products from lot number 224268 immediately. Those who purchased the product directly from MediNatura may contact the company for refunds at recall@medinatura.com. Customers who obtained the product through retailers should return it to the place of purchase.
Any individual who has experienced potential treatment-related health issues should consult their healthcare provider for evaluation. Adverse reactions can also be reported to the FDA’s MedWatch Adverse Event Reporting program, ensuring timely analysis by regulatory authorities.
FDA regulatory oversight
This recall is taking place under the observation of the U.S. Food and Drug Administration (FDA). While the FDA shares recall announcements as a public service, it does not endorse specific products or manufacturers. The agency’s involvement underscores the importance of public health safeguards in addressing potential risks associated with medical products.
How consumers can report adverse events
Consumers may directly report adverse events or concerns about product quality to the FDA through its MedWatch program. Reports can be submitted online at www.fda.gov/medwatch/report.htm, or via mail or fax by downloading the appropriate forms from www.fda.gov/MedWatch/getforms.htm. Alternatively, individuals may call 1-800-332-1088 to request reporting materials.
What this means for stakeholders
This recall highlights the critical need for stringent quality assurance in pharmaceutical manufacturing and supply chain management. Regulatory professionals and healthcare providers should evaluate how this recall impacts patient safety and workflow requirements, especially in settings serving immunocompromised populations.
Disclaimer
This post is intended for informational purposes and should not be considered legal or clinical advice. Regulatory and healthcare professionals should consult official FDA announcements and legal advisors for compliance-related decisions.